{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-265260","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2022-10-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.692522+00:00","generated_at":"2026-06-23T02:42:08.561949+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"President of R&D Judith Dunn resigns; position eliminated; CEO assumes direct oversight","bullets":["Dr. Judith Dunn resigns as president, R&D; separation agreement signed October 14, 2022.","Dunn remains employed through Jan 3, 2023, then provides biotech consulting in transitional capacity.","Clinical development organization now reports directly to CEO Bryan Stuart; president R&D role eliminated.","Company continues search for Chief Medical Officer as previously announced.","Extended 6-month exercise period for stock options post-separation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-265260","json":"https://secwatch.observer/filing/0001193125-22-265260.json","markdown":"https://secwatch.observer/filing/0001193125-22-265260.md","text":"https://secwatch.observer/filing/0001193125-22-265260.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522265260/0001193125-22-265260-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522265260/d327131d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T02:42:08.561949+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12df3057af","claim":"Judith A. Dunn resigned as president, research and development at Fulcrum Therapeutics, Inc..","evidence_excerpt":"Dr. Judith A. Dunn entered into a separation agreement subsequent to Dr. Dunn’s resignation from her position as president, research and development.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522265260/0001193125-22-265260-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"president, research and development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}